Article
Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease.
Circulation research - 23 Jun 2017
Nomura Akihiro, Won Hong-Hee, Khera Amit V, Takeuchi Fumihiko, Ito Kaoru, McCarthy Shane, Emdin Connor A, Klarin Derek, Natarajan Pradeep, Zekavat Seyedeh M, Gupta Namrata, Peloso Gina M, Borecki Ingrid B, Teslovich Tanya M, Asselta Rosanna, Duga Stefano, Merlini Piera A, Correa Adolfo, Kessler Thorsten, Wilson James G, Bown Matthew J, Hall Alistair S, Braund Peter S, Carey David J, Murray Michael F, Kirchner H Lester, Leader Joseph B, Lavage Daniel R, Manus J Neil, Hartze Dustin N, Samani Nilesh J, Schunkert Heribert, Marrugat Jaume, Elosua Roberto, McPherson Ruth, Farrall Martin, Watkins Hugh, Juang Jyh-Ming J, Hsiung Chao A, Lin Shih-Yi, Wang Jun-Sing, Tada Hayato, Kawashiri Masa-Aki, Inazu Akihiro, Yamagishi Masakazu, Katsuya Tomohiro, Nakashima Eitaro, Nakatochi Masahiro, Yamamoto Ken, Yokota Mitsuhiro, Momozawa Yukihide, Rotter Jerome I, Lander Eric S, Rader Daniel J, Danesh John, Ardissino Diego, Gabriel Stacey, Willer Cristen J, Abecasis Goncalo R, Saleheen Danish, Kubo Michiaki, Kato Norihiro, Ida Chen Yii-Der, Dewey Frederick E, Kathiresan Sekar
Abstract excerpt
RATIONALE: Therapies that inhibit CETP (cholesteryl ester transfer protein) have failed to demonstrate a reduction in risk for coronary heart disease (CHD). Human DNA sequence variants that truncate the CETP gene may provide insight into the efficacy of CETP inhibition. OBJECTIVE: To test whether protein-truncating variants (PTVs) at the CETP gene were associated with plasma lipid levels and CHD. METHODS AND...
Read the complete abstract on PubMed